Lewy Body Dementia Global Market Report 2025

The lewy body dementia market size has grown strongly in recent years. It will grow from $1.12 billion in 2024 to $1.21 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth during the historic period can be attributed to the rising aging population, increased awareness of neurodegenerative diseases, higher healthcare expenditures, improved diagnostic criteria, and regulatory approvals for dementia medications.

The lewy body dementia market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. In the forecast period, growth is expected to be driven by the increasing prevalence of dementia, greater investment in research and development, rising demand for early diagnosis, expanded adoption of telemedicine, and a growing focus on personalized medicine. Key trends anticipated include the development of targeted therapies, expansion of clinical trials, advancements in diagnostic techniques, technological innovations, and an emphasis on novel therapeutics.

The increasing prevalence of brain-related disorders is expected to drive the growth of the Lewy body dementia market. Brain-related disorders encompass a range of conditions that affect the brain’s structure and function, leading to cognitive decline, memory loss, and behavioral changes. The rising occurrence of these disorders is attributed to factors such as aging, genetic predisposition, and environmental influences. As brain-related disorders become more common, the demand for improved treatments and early detection for Lewy body dementia is also rising. This increased demand accelerates research, funding, and innovation, leading to faster advancements in diagnosis and therapy for the condition. For instance, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that over 40% of the global population is affected by neurological conditions, with this burden projected to nearly double by 2050. Therefore, the rising prevalence of brain-related disorders is expected to contribute to the expansion of the Lewy body dementia market.

Leading companies in the Lewy body dementia market are prioritizing research investments to develop more effective treatments for neurodegenerative diseases. Research investment involves allocating financial resources, time, and effort to scientific and technological studies aimed at gaining new insights, developing innovative solutions, and enhancing existing treatments. Such investments support disease exploration and the development of new medications, ultimately improving patient outcomes. For example, in March 2023, the National Institute on Aging, a US-based government agency, awarded $21 million to fund drug development research for Lewy body dementia (LBD). Researchers at the University of Miami Miller School of Medicine have launched a Phase 2b study of neflamapimod following promising early results.

In March 2023, CND Life Sciences, a US-based developer of highly accurate skin-based tests for diagnosing dementia with Lewy bodies, partnered with Beth Israel Deaconess Medical Center (BIDMC) to enhance its diagnostic tool for neurodegenerative diseases. This collaboration aims to leverage advanced technology to improve the detection of misfolded alpha-synuclein proteins and explore additional protein markers linked to other neurodegenerative conditions. The goal is to facilitate more accurate diagnoses and enhance patient outcomes as new therapies become available. Beth Israel Deaconess Medical Center (BIDMC) is a US-based institution specializing in diagnosing and treating conditions such as Lewy body disease.

Major players in the lewy body dementia market are Eli Lilly and Company, Mayo Foundation for Medical Education and Research, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Georgetown University Medical Center, Alzheimer's Society, BioArctic AB, Annovis Bio Inc., Sun Pharma Advanced Research Company Limited, Voyager Therapeutics Inc., Cognition Therapeutics, Athira Pharma, Allergan plc, Inhibikase Therapeutics, CuraSen Therapeutics Inc., CervoMed Inc., AC Immune SA, ProMIS Neurosciences Inc., Aptinyx Inc., and EIP Pharma Inc.

North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lewy body dementia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lewy body dementia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lewy body dementia (LBD) is a neurodegenerative disorder caused by abnormal protein deposits in the brain, affecting cognition, movement, and behavior. This leads to a gradual decline in both mental and physical abilities, with symptoms such as memory loss, hallucinations, tremors, and motor impairments. Proper management is crucial to address the cognitive and physical challenges associated with the condition.

Primary diagnosis of Lewy body dementia is conducted through clinical and biomarker-based methods. Clinical diagnosis involves assessing medical history, symptoms, and physical examinations to facilitate early detection and treatment. Management of the condition includes medications such as cholinesterase inhibitors, antipsychotics, and antidepressants. Various healthcare settings, including hospitals, specialty clinics, and long-term care facilities, play a crucial role in providing treatment and support.

The lewy body dementia market research report is one of a series of new reports that provides lewy body dementia market statistics, including the lewy body dementia industry global market size, regional shares, competitors with the lewy body dementia market share, detailed lewy body dementia market segments, market trends, and opportunities, and any further data you may need to thrive in the lewy body dementia industry. This lewy body dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lewy body dementia market consists of revenues earned by entities by providing services such as cognitive and motor function therapies, pharmaceutical treatments, and physical therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The lewy body dementia market also includes sales of sleep aids, mood stabilizers, and anxiolytics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.